The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

资产类别

Equity

发行方

ALPS Funds

注册地

US

成立日期

2014年12月30日

持仓数量

103

ISIN

US00162Q5936